Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Galmed Pharmaceuticals Ltd. - Ordinary Shares (GLMD)
Last galmed pharmaceuticals ltd. - ordinary shares earnings: 3/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
galmedpharma.investorroom.com
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
GLMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GLMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GLMD alerts
High impacting Galmed Pharmaceuticals Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
GLMD
News
- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Galmed publishes Results from Aramchol Phase 3 Open Label part in HepatologyPR Newswire
- Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic DiseasesPR Newswire
- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
GLMD
Sec Filings
- 11/22/24 - Form EFFECT
- 11/14/24 - Form 6-K
- 11/14/24 - Form F-3
- GLMD's page on the SEC website